Blood Res.  2015 Sep;50(3):173-178. 10.5045/br.2015.50.3.173.

The efficacy of bypassing agents in surgery of hemophilia patients with inhibitors

• Ju HY
• Jang HL
• Park YS

• KMID: 2172761
• DOI: http://doi.org/10.5045/br.2015.50.3.173

Abstract

BACKGROUND
Inhibitory antibodies to factor VIII (FVIII) or IX (FIX) are important issues when managing patients with hemophilia A or B. Advances in bypassing agents such as recombinant activated FVII (rFVIIa) and activated prothrombin complex concentrates (APCC) have enabled the aggressive management of hemophilia with inhibitors during emergency or elective surgery. This study provides an updated evaluation of the safety and effectiveness of bypassing agents in treating perioperative bleeding.
METHODS
We reviewed the records of hemophilia patients with inhibitors who underwent surgery between May 2008 and July 2014 using bypassing agents or high-dose FVIII concentrates at a single center.
RESULTS
In total, 36 surgeries (24 orthopedic, 12 other) were conducted in 18 hemophilia patients with inhibitors. The median inhibitor titer at surgery was 14 (range, 0.7-1,900) Bethesda units. Most patients had high-responding inhibitors. In total, 25 patients received APCC, 9 with rFVIIa initially. In most cases, bleeding stopped or was well controlled; however, bleeding in 6 patients was controlled using sequential bypassing therapy. Hemostatic efficacy of bypassing agents in various surgeries, based on the final patient outcome, was 94.4% (34/36). Among 5 emergency surgeries, 2 deaths occurred.
CONCLUSION
Good control of hemostasis can be achieved using bypassing agents in hemophilia patients with inhibitors who are undergoing surgery. Thorough planning is needed before elective surgery and more active and aggressive management may be needed for emergency surgery. Use of bypassing agents can facilitate safe and successful surgeries in hemophilia patients with inhibitors.

Keyword

Hemophilia; Inhibitor; Bypassing agent; Surgery

MeSH Terms

Antibodies
Emergencies
Factor VIII
Hemophilia A*
Hemorrhage
Hemostasis
Humans
Orthopedics
Prothrombin
Antibodies
Factor VIII
Prothrombin

Reference

1. Valentino LA, Cooper DL, Goldstein B. Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX. Haemophilia. 2011; 17:579–589. PMID: 21294815.

2. Polyanskaya T, Zorenko V, Karpov E, Sampiev M, Mishin G, Vasiliev D. Experience of recombinant activated factor VII usage during surgery in patients with haemophilia with inhibitors. Haemophilia. 2012; 18:997–1002. PMID: 22672066.

3. Morfini M, Haya S, Tagariello G, et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia. 2007; 13:606–612. PMID: 17880451.

4. Yu Polyanskaya T, Khametova RN, Yu Andreev N. Development and clinical course of hemophilia complicated by the presence of an inhibitor. Haematol Transfusiol. 2002; 47:9–12.

5. Teitel JM, Carcao M, Lillicrap D, et al. Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care. Haemophilia. 2009; 15:227–239. PMID: 18752535.

6. Négrier C, Lienhart A, Numerof R, et al. SURgical interventions with FEIBA (SURF): international registry of surgery in haemophilia patients with inhibitory antibodies. Haemophilia. 2013; 19:e143–e150. PMID: 23282031.

7. Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost. 2000; 26:425–432. PMID: 11092219.

8. Lauroua P, Ferrer AM, Guérin V. Successful major and minor surgery using factor VIII inhibitor bypassing activity in patients with haemophilia A and inhibitors. Haemophilia. 2009; 15:1300–1307. PMID: 19659794.

9. Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol. 2013; 4:59–72. PMID: 23610614.

10. FEIBA. VH Anti-Inhibitor Coagulant Complex [package insert]. Westlake Village, CA: Baxter Healthcare Corporation;2005. Accesed May 4, 2015. at http://www.baxter.com.pr/healthcare_professionals/products/feiba_vh.html.

11. Novo Nordisk A/S. NovoSeven [package insert]. Novo Nordisk A/S. Bagsvaerd, Denmark: Novo Nordisk A/S;2005. Accesed May 4, 2015. at http://www.novo-pi.com/novosevenrt.pdf.

12. Teitel J, Berntorp E, Collins P, et al. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia. 2007; 13:256–263. PMID: 17498074.

13. Scharrer I. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Haemophilia. 1999; 5:253–259. PMID: 10469179.

14. Han MH, Park YS. Sequential therapy with activated prothrombin complex concentrates and recombinant activated factor VII to treat unresponsive bleeding in patients with hemophilia and inhibitors: a single center experience. Blood Res. 2013; 48:282–286. PMID: 24466553.

15. Caviglia H, Candela M, Galatro G, Neme D, Moretti N, Bianco RP. Elective orthopaedic surgery for haemophilia patients with inhibitors: single centre experience of 40 procedures and review of the literature. Haemophilia. 2011; 17:910–919. PMID: 21342367.

16. Ludlam CA, Smith MP, Morfini M, Gringeri A, Santagostino E, Savidge GF. A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. Br J Haematol. 2003; 120:808–813. PMID: 12614214.

17. Hirose J, Takedani H, Koibuchi T. The risk of elective orthopaedic surgery for haemophilia patients: Japanese single-centre experience. Haemophilia. 2013; 19:951–955. PMID: 23746133.

18. Berntorp E, Collins P, D'Oiron R. . Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition. Haemophilia. 2011; 17:e202–e210. PMID: 20825500.

19. Young G, Blain R, Nakagawa P, Nugent DJ. Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia. 2006; 12:598–604. PMID: 17083509.

20. Váradi K, Negrier C, Berntorp E, et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost. 2003; 1:2374–2380. PMID: 14629472.

21. Giangrande PL, Wilde JT, Madan B, et al. Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia. 2009; 15:501–508. PMID: 19187194.

22. Rangarajan S, Austin S, Goddard NJ, et al. Consensus recommendations for the use of FEIBA(®) in haemophilia A patients with inhibitors undergoing elective orthopaedic and nonorthopaedic surgery. Haemophilia. 2013; 19:294–303. PMID: 22989234.